
Quarterly report 2025-Q3
added 11-17-2025
AIM ImmunoTech Market Cap 2011-2026 | AIM
As of March 26, 2026 AIM ImmunoTech has a market cap of $ 41.4 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap AIM ImmunoTech
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.2 M | 44.2 M | 79 M | 3.68 M | 9.72 M | 14.6 M | 14.4 M | 21.3 M | 41.4 M | 73.6 M | 42.3 M | 63.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 79 M | 3.68 M | 35.7 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Precigen
PGEN
|
970 M | $ 3.1 | -0.96 % | $ 758 M | ||
|
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | ||
|
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
127 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
7.37 B | $ 220.9 | 2.49 % | $ 5 B | ||
|
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 19.57 | 1.77 % | $ 915 M | ||
|
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.33 | 0.76 % | $ 339 M | ||
|
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
67 M | - | - | $ 546 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
68.7 M | $ 1.58 | 6.04 % | $ 99.5 M | ||
|
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
54.1 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
1.82 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | ||
|
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 8.31 | 1.59 % | $ 111 M | ||
|
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 47.09 | 1.42 % | $ 4.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.53 | 5.1 % | $ 868 M | ||
|
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | ||
|
CytomX Therapeutics
CTMX
|
931 M | $ 4.22 | -0.47 % | $ 582 M | ||
|
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
960 M | - | -10.95 % | $ 876 K | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
Cyclacel Pharmaceuticals
CYCC
|
5.58 M | - | -5.98 % | $ 34.1 M |